Novavax reports Q3 EPS ($2.15) vs. ($4.31) last year

Reports Q3 revenue $734.6M, consensus $586.25M. "Our progress in the third quarter continued as we successfully expanded our COVID-19 vaccine’s label, achieved policy recommendations globally and expanded our body of clinical evidence supporting the differentiated benefit of our vaccine technology," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "New data that we announced today reaffirms the broad immune responses of NVX-CoV2373 against circulating variants. Additionally, based on our most recent Phase 1/2 trial results for our COVID-19-Influenza Combination vaccine candidate, we look forward to initiating our Phase 2 clinical trial by the end of this year."